{'fraction_non_alphanumeric': 0.02301410541945063, 'fraction_numerical': 0.0022271714922048997, 'mean_word_length': 5.543689320388349, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Lentiviral Gene Therapy for X-Linked Chronic Granulomatous Recapitulates Endogenous CYBB Regulation and Expression.

X-Linked Chronic Granulomatous Disease (X-CGD) is a primary immunodeficiency caused by mutations in the CYBB gene resulting in the inability of phagocytic cells to eliminate infections. In order to design a lentiviral vector capable of recapitulating the endogenous regulation and expression of CYBB, a bioinformatics-guided approach was utilized to elucidate the cognate enhancer elements regulating the native CYBB gene. Using this approach, we analyzed a 600 kb topologically associated domain of the CYBB gene and identified endogenous enhancer elements to supplement the CYBB promoter to develop MyeloVec, a physiologically regulated lentiviral vector (LV) for the treatment of X-CGD. When compared to a LV currently in clinical trials for X-CGD, MyeloVec showed improved expression, superior gene transfer to hematopoietic stem and progenitor cells (HSPCs), corrected an X-CGD mouse model leading to complete protection against B. cepacia infection, and restored healthy donor levels of anti-microbial oxidase activity in neutrophils derived from X-CGD patient HSPCs. Our findings validate the bioinformatics-guided design approach and have yielded a novel lentiviral vector with clinical promise for the treatment of X-CGD.